
1. Short title
This Act may be cited as the Studying Suboxone Act. 2. Reviewing the scheduling of buprenorphine-naloxone combination products
 (a) Secretary of HHS
The Secretary of Health and Human Services shall—

(1) review and, as appropriate, update the scientific and medical evaluation conducted under section 201(b) of the Controlled Substance Act (21 U.S.C. 811(b)) with respect to buprenorphine-naloxone combination products; and 
(2) update, as necessary, the Secretary’s scheduling recommendation under such section with respect to such products.
(b) Attorney General
The Attorney General shall— 
(1) review the recommendations provided by the Secretary under subsection (a), and all other relevant data with respect to the scheduling of buprenorphine-naloxone combination products;

(2) consider the factors listed in subsection (c) of section 201 of the Controlled Substance Act (21 U.S.C. 811) with respect to such products; and 
(3) consistent with such section 201, make such scheduling changes with respect to such products as the Secretary may determine appropriate.
